4.26
price up icon3.15%   0.13
after-market Dopo l'orario di chiusura: 4.24 -0.02 -0.47%
loading
Precedente Chiudi:
$4.13
Aprire:
$4.17
Volume 24 ore:
165.31K
Relative Volume:
1.19
Capitalizzazione di mercato:
$57.66M
Reddito:
$52.29M
Utile/perdita netta:
$-73.52M
Rapporto P/E:
-6.4545
EPS:
-0.66
Flusso di cassa netto:
$-100.45M
1 W Prestazione:
+0.47%
1M Prestazione:
-15.48%
6M Prestazione:
-9.17%
1 anno Prestazione:
-54.73%
Intervallo 1D:
Value
$4.13
$4.30
Intervallo di 1 settimana:
Value
$4.02
$4.38
Portata 52W:
Value
$3.61
$11.09

Precision Biosciences Inc Stock (DTIL) Company Profile

Name
Nome
Precision Biosciences Inc
Name
Telefono
919-314-5512
Name
Indirizzo
302 EAST PETTIGREW STREET, DURHAM, NC
Name
Dipendente
107
Name
Cinguettio
@PrecisionBioSci
Name
Prossima data di guadagno
2024-11-04
Name
Ultimi documenti SEC
Name
DTIL's Discussions on Twitter

Confronta DTIL con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
DTIL
Precision Biosciences Inc
4.26 57.66M 52.29M -73.52M -100.45M -0.66
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Precision Biosciences Inc Stock (DTIL) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-01-10 Aggiornamento BMO Capital Markets Market Perform → Outperform
2024-04-30 Iniziato Guggenheim Buy
2022-06-17 Iniziato BMO Capital Markets Outperform
2022-06-09 Downgrade William Blair Outperform → Mkt Perform
2020-07-27 Ripresa BTIG Research Buy
2020-04-03 Downgrade Goldman Buy → Neutral
2020-03-05 Iniziato Stifel Buy
2020-02-25 Iniziato William Blair Outperform
2019-08-09 Iniziato BTIG Research Buy
2019-07-16 Iniziato H.C. Wainwright Buy
2019-04-22 Iniziato Barclays Overweight
2019-04-22 Iniziato Goldman Buy
2019-04-22 Iniziato JP Morgan Overweight
2019-04-22 Iniziato Jefferies Buy
Mostra tutto

Precision Biosciences Inc Borsa (DTIL) Ultime notizie

pulisher
Jun 03, 2025

precision biosciences reports voting outcomes at annual shareholder meeting By Investing.com - Investing.com Australia

Jun 03, 2025
pulisher
Jun 03, 2025

precision biosciences reports voting outcomes at annual shareholder meeting - Investing.com

Jun 03, 2025
pulisher
Jun 03, 2025

Precision BioSciences Holds Annual Stockholder Meeting - TipRanks

Jun 03, 2025
pulisher
May 21, 2025

Precision BioSciences (DTIL): Rating Reaffirmed at Buy with $60 Target | DTIL Stock News - GuruFocus

May 21, 2025
pulisher
May 19, 2025

(DTIL) Proactive Strategies - news.stocktradersdaily.com

May 19, 2025
pulisher
May 16, 2025

Precision BioSciences: Q1 Earnings Snapshot - CT Insider

May 16, 2025
pulisher
May 16, 2025

Precision BioSciences Reports Q1 2025 Financial Results - TipRanks

May 16, 2025
pulisher
May 15, 2025

Transcript : Precision BioSciences, Inc.Special Call - marketscreener.com

May 15, 2025
pulisher
May 15, 2025

Precision BioSciences Inc Reports Q1 2025 EPS of $(2.21) and Rev - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Precision BioSciences Reports Q1 Results and Business Update - TipRanks

May 15, 2025
pulisher
May 15, 2025

Precision BioSciences (DTIL) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance

May 15, 2025
pulisher
May 15, 2025

Precision BioSciences (DTIL) Reports Robust Q1 Revenue and Advan - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Precision BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update - BioSpace

May 15, 2025
pulisher
May 15, 2025

Precision BioSciences Reports First Quarter 2025 Financial Resul - GuruFocus

May 15, 2025
pulisher
May 15, 2025

DTIL Reports Strong Start to 2025 with Clinical Progress | DTIL Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Precision BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update | DTIL Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Precision Biosciences Q1 Income From Operations USD -22.112 Million - marketscreener.com

May 15, 2025
pulisher
May 14, 2025

Precision BioSciences Accelerates Development of PBGENE-DMD Within its Wholly Owned Organic Pipeline and Highlights Pre-clinical Evidence at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting - BioSpace

May 14, 2025
pulisher
May 14, 2025

Precision BioSciences Accelerates PBGENE-DMD Program for DMD - TipRanks

May 14, 2025
pulisher
May 14, 2025

Precision BioSciences Accelerates Development of PBGENE-DMD With - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Anti-CD152 Antibody Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Precision Biosciences, TG Therapeutics, RemeGen, Caribou Biosciences - Barchart.com

May 14, 2025
pulisher
May 08, 2025

Precision BioSciences to Report First Quarter 2025 Results on May 15, 2025 - BioSpace

May 08, 2025
pulisher
May 08, 2025

Precision BioSciences to Report First Quarter 2025 Results on May 15, 2025 | DTIL Stock News - GuruFocus

May 08, 2025
pulisher
May 07, 2025

Precision BioSciences Announces Presentation of Initial Safety Data from the Phase 1 ELIMINATE-B Trial Evaluating PBGENE-HBV at the 2025 European Association for the Study of the Liver Congress (EASL) - GuruFocus

May 07, 2025
pulisher
May 06, 2025

iECURE to Present Initial OTC-HOPE Clinical Data of ECUR-506 in Ornithine Transcarbamylase Deficiency at Upcoming Medical Meetings - Business Wire

May 06, 2025
pulisher
May 01, 2025

Precision BioSciences Announces Multiple Presentations for In Vivo Gene Editing Programs at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting - BioSpace

May 01, 2025
pulisher
May 01, 2025

Precision BioSciences Announces Multiple Presentations for In Vivo Gene Editing Programs at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting | DTIL Stock News - GuruFocus

May 01, 2025
pulisher
Apr 29, 2025

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) April 29, 2025 - BioSpace

Apr 29, 2025
pulisher
Apr 29, 2025

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com

Apr 29, 2025
pulisher
Apr 29, 2025

Precision BioSciences Strengthens Gene Editing Team with Strategic RSU Awards to New Hires - Stock Titan

Apr 29, 2025
pulisher
Apr 23, 2025

Trading (DTIL) With Integrated Risk Controls - news.stocktradersdaily.com

Apr 23, 2025
pulisher
Apr 16, 2025

DTIL Gets FDA's Fast Track Tag for Hepatitis B Gene Therapy, Stock Up - TradingView

Apr 16, 2025
pulisher
Apr 16, 2025

Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B | DTIL Stock News - GuruFocus

Apr 16, 2025
pulisher
Apr 15, 2025

FDA fast tracks Precision BioSciences’ hepatitis B treatment By Investing.com - Investing.com South Africa

Apr 15, 2025
pulisher
Apr 15, 2025

Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B - BioSpace

Apr 15, 2025
pulisher
Apr 15, 2025

Precision BioSciences stock rises following FDA Fast Track designation By Investing.com - Investing.com India

Apr 15, 2025
pulisher
Apr 15, 2025

Precision BioSciences Gets FDA Fast Track Label for PBGENE-HBV - marketscreener.com

Apr 15, 2025
pulisher
Apr 15, 2025

12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga

Apr 15, 2025
pulisher
Apr 15, 2025

FDA Fast Tracks Precision BioSciences' (DTIL) Hepatitis B Gene E - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

FDA fast tracks Precision BioSciences’ hepatitis B treatment - Investing.com Australia

Apr 15, 2025
pulisher
Apr 15, 2025

Precision BioSciences stock rises following FDA Fast Track designation - Investing.com Australia

Apr 15, 2025
pulisher
Apr 15, 2025

FDA Fast Tracks Precision BioSciences' (DTIL) Hepatitis B Gene Editing Program | DTIL Stock News - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Precision Biosciences Receives U.S. FDA Fast Track Designation For Pbgene-Hbv - marketscreener.com

Apr 15, 2025

Precision Biosciences Inc Azioni (DTIL) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Precision Biosciences Inc Azioni (DTIL) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Buehler Kevin
Director
Jun 25 '25
Buy
4.16
5,076
21,116
28,137
Buehler Kevin
Director
Mar 26 '25
Buy
4.67
4,523
21,122
13,235
Brown Melinda
Director
Mar 26 '25
Buy
4.75
1,839
8,735
9,057
Germano Geno J
Director
Mar 25 '25
Buy
5.30
3,250
17,225
11,057
Amoroso Michael
President and CEO
Mar 24 '25
Sale
5.56
964
5,360
109,540
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.23
price up icon 0.63%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Capitalizzazione:     |  Volume (24 ore):